Jiayang Chen, MD, PhD | Chinese Academy of Medical Sciences; Li Feng, MD, PhD; Peizhi Ye, MD; Xinrui Hu, MS; Xinqi Liu, MS; Ning Du, MS; Qiyuan Mao, MD
Competition Sponsor: Chinese Academy of Medical Sciences
Awardee Year: 2025
Chemotherapy-induced gastrointestinal reactions significantly impact patients’ quality of life and survival, with nausea and vomiting being the most prevalent symptoms. Routine prophylactic use of antiemetics like 5-HT3 receptor antagonists achieves a high efficacy rate of approximately 70%–84%. However, patients responding to antiemetic therapy may still experience symptoms such as loss of appetite, nausea, bloating, and constipation during chemotherapy, highlighting the limitations of modern medical approaches in providing holistic management.
Our team has developed the patented Chinese herbal formula Jianpi Yiwei Formula (ZL202210097886.0) for chemotherapy-induced gastrointestinal reactions. Preliminary clinical results show an overall efficacy rate of 85% in alleviating these symptoms. Standardized granule preparation has been completed, including studies on manufacturing, pharmacodynamics, quality control, and stability. Preliminary research indicates that modulating the “inflammation-gut microbiota axis” is its core mechanism.
This project aims to build on prior findings by completing toxicology studies, obtaining robust clinical efficacy evidence through standardized trials, and exploring mechanisms via patient samples. The goal is to establish a closed-loop R&D and clinical application framework for Jianpi Yiwei Formula—ensuring quality control, confirmed efficacy, and clarified mechanisms.